Synlogic (SYBX) Stock Price, News & Analysis

Company Overview

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.22 to $1.22
• 50-Day Range: $0.67 to $1.23
• 52-Week Range: $0.54 to $1.87
• Volume: 117 shs
• Average Volume: 73,173 shs
• Market Capitalization: $14.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Synlogic Stock Analysis - MarketRank™

Synlogic scored higher than 2% of companies evaluated by MarketBeat, and ranked 908th out of 916 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Synlogic has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Synlogic has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Synlogic are expected to grow in the coming year, from ($2.71) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Synlogic is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synlogic is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synlogic has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SYBX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synlogic does not currently pay a dividend.

Dividend Growth

Synlogic does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Synlogic this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for SYBX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synlogic insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.62% of the stock of Synlogic is held by insiders.

Percentage Held by Institutions

63.40% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/13/2025
• Today: 9/02/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SYBX
• CIK: 1527599
• Web: www.synlogictx.com
• Phone: (617) 401-9975
• Fax: 512-681-5201
• Employees: 80
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.47%
• Return on Assets: -18.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.65
• Quick Ratio: 2.65

Sales & Book Value

• Annual Sales: $8 thousand
• Price / Sales: 1,867.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.09 per share
• Price / Book: 1.12

Miscellaneous

• Outstanding Shares: 12,249,000
• Free Float: 11,392,000
• Market Cap: $14.94 million
• Optionable: No Data
• Beta: 0.48